Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus plus standard therapy vs placebo in elderly patients with newly diagnosed AML
2011-002365-37Phase 2Completed
- Sponsor
- Goethe University Frankfurt
- Start
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Temsirolimus + standard primary chemotherapy with Placebo + standard primary chemotherapy (2 arms). Primary endpoint: Median event-free survival. Started Jan 2012; status: completed.
02
Drugs
temsirolimus
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2011-002365-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002365-37.